Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Justin Franklin Gainor, M.D.

Co-Author

This page shows the publications co-authored by Justin Gainor and Meghan Mooradian.
Connection Strength

3.147
  1. Putting the brakes on CTLA-4 inhibition in lung cancer? Transl Lung Cancer Res. 2018 Feb; 7(Suppl 1):S35-S38.
    View in: PubMed
    Score: 0.766
  2. ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack. Oncologist. 2017 07; 22(7):759-761.
    View in: PubMed
    Score: 0.734
  3. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist. 2017 01; 22(1):81-88.
    View in: PubMed
    Score: 0.346
  4. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.232
  5. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411.
    View in: PubMed
    Score: 0.218
  6. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019 06; 48(6):1127-1132.
    View in: PubMed
    Score: 0.201
  7. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. J Thorac Oncol. 2016 11; 11(11):1869-1878.
    View in: PubMed
    Score: 0.173
  8. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433.
    View in: PubMed
    Score: 0.060
  9. Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer. Eur J Cancer. 2021 04; 147:13-16.
    View in: PubMed
    Score: 0.059
  10. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.054
  11. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.054
  12. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. JAMA Netw Open. 2019 09 04; 2(9):e1911952.
    View in: PubMed
    Score: 0.053
  13. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365.
    View in: PubMed
    Score: 0.052
  14. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Mod Pathol. 2019 04; 32(4):511-523.
    View in: PubMed
    Score: 0.050
  15. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  16. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.